Please login to the form below

Not currently logged in
Email:
Password:

prostate cancer

This page shows the latest prostate cancer news and features for those working in and with pharma, biotech and healthcare.

CRUK forges £30m ‘post-Brexit’ R&D alliance

CRUK forges £30m ‘post-Brexit’ R&D alliance

One UK project – called HUNTER - is getting £5m to look into immunotherapies for liver cancer and will be led by Newcastle University. ... The University of Trento is leading on a project worth around £5m to develop a blood test for advanced prostate

Latest news

  • UK start-up Azeria emerges with £4m drug discovery pot for cancer UK start-up Azeria emerges with £4m drug discovery pot for cancer

    The company is focusing on hormone resistant breast and prostate cancer. ... The new drug discovery company is focusing on hormone resistant breast and prostate cancer, and specifically drugs that target ‘pioneer’transcription factors – which

  • Healthcare Comms round up Healthcare Comms round up

    Last year’s funding helped us to produce powerful projects based around mental health, prostate cancer and the sugar tax, we can't wait to see where this years funding takes ... The Difference Collective was launched last June by Virgo Health

  • CHMP turns down BMS’ Opdivo/Yervoy for kidney cancer CHMP turns down BMS’ Opdivo/Yervoy for kidney cancer

    precursor acute lymphoblastic leukaemia (ALL) patients with residual cancer cells after prior treatment. ... Finally, the CHMP said after a review of the clinical data for Bayer’s metastatic prostate cancer therapy Xofigo (radium-223 dichloride) that

  • AbbVie’s blockbuster-in-waiting for endometriosis gets FDA nod AbbVie’s blockbuster-in-waiting for endometriosis gets FDA nod

    Their relugolix candidate has positive mid-stage results in endometriosis-related pain, uterine fibroids, and prostate cancer, and is currently in phase III testing with some results due next year.

  • MaxCyte gets green light for solid tumour cell therapy MaxCyte gets green light for solid tumour cell therapy

    MaxCyte gets green light for solid tumour cell therapy. Its first CAR therapy will be tested in patients with ovarian cancer. ... Mesothelin is expressed at elevated levels by a number of cancer types, including prostate and bile duct cancer, and  has

More from news
Approximately 49 fully matching, plus 313 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    13 new targeted medicines that block the growth and spread of cancer by interfering with specific molecular targets. ... and ovarian cancer, and some tumours such as pancreatic and prostate cancers have proved resistant to current immunotherapies.

  • Erectile dysfunction, constipation, vaginal dryness and other laughing matters Erectile dysfunction, constipation, vaginal dryness and other laughing matters

    Billy Connolly received the news of his diagnosis for dementia and prostate cancer on the same day:. ... And on the Wednesday I got news that I had prostate cancer and Parkinson’s disease… But when we went into the living room I went, phrrhrht, ”he

  • Deal Watch February 2017 Deal Watch February 2017

    In February, it granted North American rights to Zoladex, a goserelin acetate implant for prostate and breast cancer and benign gynaecological disorders, to US company TerSera Therapeutics. ... Licence. 358. AstraZeneca/ TerSera Therapeutics. Zoladex,

  • Deal Watch September 2016 Deal Watch September 2016

    At a lower disclosed headline value of $310m BioNTech licensed its mRNA-based cancer vaccines platform to Genentech. ... Janssen granted Tracon Pharmaceuticals the rights to develop two oncology programmes for prostate cancer and haematological

  • Deal Watch August 2016 Deal Watch August 2016

    35! Although Pfizer pointed to the $2.2bn of Xtandi sales for advanced metastatic prostate cancer, this product has been under licence to Astellas since 2009, including a US profit share ... Headline £m. Medivation (US). Pfizer (US). Company acquisition.

More from intelligence
Approximately 1 fully matching, plus 38 partially matching documents found.

Latest appointments

  • Dendreon appoints new R&D lead Dendreon appoints new R&D lead

    urologists who are uniquely positioned to deliver long-term care to men with prostate cancer. ... stage prostate cancer, with the hope of curing more men of the disease.”.

  • Astellas bolsters oncology clinical development leadership Astellas bolsters oncology clinical development leadership

    breast cancer, leukaemia, lung cancer and prostate cancer. ... of Medicine and the University of Texas MD Anderson Cancer Center.

  • Astellas promotes John Demaree Astellas promotes John Demaree

    Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib). ... Mark Reisenauer, senior vice

  • MDxHealth creates new global commercial team MDxHealth creates new global commercial team

    MDxHealth has created a new global commercial team to drive the launch of SelectMDx, its new prostate cancer test. ... the commercialisation of a molecular diagnostic test for prostate cancer across Europe.”.

  • Dr Hamina Patel moves from J&J to Evgen Pharma Dr Hamina Patel moves from J&J to Evgen Pharma

    She joins the firm from Johnson and Johnson, where she was director of drug development, oncology, where she helped to build a broad portfolio of indications for its cancer drug Velcade. ... interest in prostate cancer.

More from appointments
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest from PMHub

  • Successful brands tell stories

    An oncology tale. In 2017 Blue Latitude Health was asked to develop differentiated and convincing global messaging for physicians helping prostate cancer patients.

  • Porterhouse Medical strengthens the team with three new members.

    Alex is relocating from Scotland, where he completed a research MSc in molecular and clinical medicine focused on castrate-resistant prostate cancer at the University of Edinburgh.

  • Infographic: Prostate Cancer Market Snapshot

    Infographic: Prostate Cancer Market Snapshot. An overview of the prostate cancer patient. ... Download our Therapy Watch PCa market snapshot which provides you with an overview of the prostate cancer patient and the therapy regimens followed by the

  • Hayward Medical Communications continues partnership with Prostate Cancer UK

    Hayward Medical Communications continues partnership with Prostate Cancer UK. Long-standing relationship creates new ventures. ... Most recently, Hayward and Prostate Cancer UK have begun a new project to further improve the patient journey.

  • Caring for prostate cancer patients

    Associate Consultant Frances Peters takes a look at the issues and concerns facing the caregivers of those with prostate cancer. ... From a personal perspective, I’ ve watched my grandfather receive his diagnosis of prostate cancer.

More from PMHub
Approximately 7 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you into the world of the patient....

Latest intelligence

Solaris Health looks at the gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics